UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in PHVS — Pharvaris N.V.

CIK 861177 NEW YORK, NY

Back to PHVS Full portfolio

Position in PHVS

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$2,193,499

-$136,030 QoQ

Shares Held

77,646

-7.5% QoQ

Ownership

0.111%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2024

6 quarters on record

Voting authority Sole 22.85758442160575.ToString("F0")% Shared 0.ToString("F0")% None 77.14241557839425.ToString("F0")%

Common Shares in PHVS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,037,771 across 211 Biotechnology names. PHVS ranks #100 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,057,396	$1,365,249,602
2	REGN	Regeneron Pharmaceuticals, Inc.	723,621	$559,098,523
3	ALNY	Alnylam Pharmaceuticals, Inc.	677,519	$224,170,706
4	INSM	INSMED Inc	1,215,025	$198,680,883
5	RPRX	Royalty Pharma plc	3,095,766	$148,503,890
6	INCY	Incyte Corp	1,540,913	$145,030,725
7	IONS	Ionis Pharmaceuticals Inc	1,475,632	$110,805,201
8	DNLI	Denali Therapeutics Inc.	4,432,314	$85,100,425

All Filings in PHVS

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,193,499	77,646	-7.5%	Shares	Defined	2026-05-13
2025-12-31	$2,329,529	83,947	+51.6%	Shares	Defined	2026-02-13
2025-06-30	$974,635	55,377	-19.0%	Shares	Sole	2025-08-14
2025-03-31	$1,072,795	68,331	+7.2%	Shares	Defined	2025-05-19
2024-12-31	$1,221,779	63,734	+30.3%	Shares	Sole	2025-02-14
2024-09-30	$905,553	48,896	—	Shares	Defined	2024-11-14
No filing history on record for this holder in this stock.